GET
/
analyst
/
insights
curl --request GET \
  --url https://api.benzinga.com/api/v1/analyst/insights
{
"action": "Reiterates",
"analyst_insights": "This morning, HC Wainwright & Co. reiterated their Buy rating on Cybin's stock with a price target of $5.0000. - **Advancing Clinical Pipeline:** Cybin is making significant strides in its clinical development programs, with a focus on progressing CYB003 for major depressive disorder (MDD) and CYB004 for generalized anxiety disorder (GAD) into the next phases of clinical trials. The company plans to report three-month efficacy data from a Phase 2 trial of CYB003 and is preparing for an end-of-Phase 2 meeting with the FDA, demonstrating a clear path forward for these programs.\n\n- **Positive Valuation Model:** HC Wainwright & Co. employs a discounted cash flow (DCF)-based valuation methodology, assigning a 55% probability of success for CYB003 in treating MDD and a 45% probability for CYB004 in treating GAD. These probabilities, along with planned equity raises and a conservative discount rate, support a $5 price target, suggesting confidence in Cybin’s potential market value and future revenue generation capabilities from these treatments.\n\n- **Strategic Regulatory Milestones:** Cybin has received FDA clearance to initiate a Phase 2a trial evaluating CYB004 in GAD, expected to start in 1Q24. This clearance, coupled with the planned end-of-Phase 2 meeting for CYB003, indicates regulatory progress and positions Cybin favorably for advancing its therapeutic candidates through the clinical development process, ultimately enhancing shareholder value.",
"date": "2024-02-15",
"firm": "HC Wainwright & Co.",
"firm_id": "5c383d9b0448fc02d76b09d5",
"id": "65ce4cb3ba47d164700176bf",
"pt": "5.0000",
"rating": "Buy",
"rating_id": "65ce4c5d0ebf29000101f29b",
"security": {
"cik": "",
"exchange": "AMEX",
"isin": "",
"name": "Cybin",
"symbol": "CYBN"
},
"updated": 1708018876
}

{
"action": "Reiterates",
"analyst_insights": "This morning, HC Wainwright & Co. reiterated their Buy rating on Cybin's stock with a price target of $5.0000. - **Advancing Clinical Pipeline:** Cybin is making significant strides in its clinical development programs, with a focus on progressing CYB003 for major depressive disorder (MDD) and CYB004 for generalized anxiety disorder (GAD) into the next phases of clinical trials. The company plans to report three-month efficacy data from a Phase 2 trial of CYB003 and is preparing for an end-of-Phase 2 meeting with the FDA, demonstrating a clear path forward for these programs.\n\n- **Positive Valuation Model:** HC Wainwright & Co. employs a discounted cash flow (DCF)-based valuation methodology, assigning a 55% probability of success for CYB003 in treating MDD and a 45% probability for CYB004 in treating GAD. These probabilities, along with planned equity raises and a conservative discount rate, support a $5 price target, suggesting confidence in Cybin’s potential market value and future revenue generation capabilities from these treatments.\n\n- **Strategic Regulatory Milestones:** Cybin has received FDA clearance to initiate a Phase 2a trial evaluating CYB004 in GAD, expected to start in 1Q24. This clearance, coupled with the planned end-of-Phase 2 meeting for CYB003, indicates regulatory progress and positions Cybin favorably for advancing its therapeutic candidates through the clinical development process, ultimately enhancing shareholder value.",
"date": "2024-02-15",
"firm": "HC Wainwright & Co.",
"firm_id": "5c383d9b0448fc02d76b09d5",
"id": "65ce4cb3ba47d164700176bf",
"pt": "5.0000",
"rating": "Buy",
"rating_id": "65ce4c5d0ebf29000101f29b",
"security": {
"cik": "",
"exchange": "AMEX",
"isin": "",
"name": "Cybin",
"symbol": "CYBN"
},
"updated": 1708018876
}

Authorizations

​
token
string
query
required

Query Parameters

​
page
integer
default:1

Page number for pagination.

​
pageSize
integer
default:10

Number of items per page.

​
symbols
string

Stock ticker symbols separated by commas to query for analyst insights.

​
analyst
string

One or more analyst ids separated by a comma.

​
rating_id
string

One or more rating ids separated by a comma.

​
search_keys_type
enum<string>

If you wanna query by firm Id or firm name, use this parameter and pass the key. Currently supported are [firm_id, firm]

Available options:
firm_id,
firm
​
search_keys
string

If you have selected search_keys_type, pass the appropriate identifier here.

Response

200
application/json
An array of analyst insights for the requested ticker symbol.

The response is of type object[].